PeptideDB

BOS-318 2387633-15-8

BOS-318 2387633-15-8

CAS No.: 2387633-15-8

BOS-318 is a potent, slowly dissociating, selective, cell-penetrating/penetrable Furin inhibitor (antagonist) with
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

BOS-318 is a potent, slowly dissociating, selective, cell-penetrating/penetrable Furin inhibitor (antagonist) with IC50 of 1.9 nM. BOS-318 protects ENaC from neutrophil elastase activation. BOS-318 may be utilized in the research/study of CF lung disease.

Physicochemical Properties


Molecular Formula C28H32CL2N6O3
Molecular Weight 571.50
Exact Mass 570.191
CAS # 2387633-15-8
PubChem CID 146241691
Appearance Off-white to light yellow solid powder
LogP 2
Hydrogen Bond Donor Count 1
Hydrogen Bond Acceptor Count 9
Rotatable Bond Count 8
Heavy Atom Count 39
Complexity 764
Defined Atom Stereocenter Count 0
InChi Key AZEJIKZNBHEXCM-UHFFFAOYSA-N
InChi Code

InChI=1S/C28H32Cl2N6O3/c1-34-6-8-36(9-7-34)28-31-16-24(17-32-28)39-26-11-20(18-35-4-2-19(3-5-35)12-27(37)38)10-25(33-26)21-13-22(29)15-23(30)14-21/h10-11,13-17,19H,2-9,12,18H2,1H3,(H,37,38)
Chemical Name

2-[1-[[2-(3,5-dichlorophenyl)-6-[2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]oxypyridin-4-yl]methyl]piperidin-4-yl]acetic acid
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro BOS-318 (0.001–1 μM, 72 hours) offers cytoprotection against CuFi-1 cytotoxicity caused by Pseudomonas aeruginosa exotoxin A (PEA) [1]. The furin-resistance of BOS-318 (U2OS cells) is roughly 13 times more than that of PCSK5 (IC50 = 25.3 nM), 24 times greater than that of PCSK7 (IC50 = 45.8 nM), and 110 times greater than that of PCSK6 (IC50 = 209.4 nM). [1]. NE and CF sputum sol-mediated ENaC activation is inhibited by BOS-318 (0.3 μM, 2 hours or 48 hours) and ENaC-mediated Na+ uptake in CF HBEC is decreased [1].
Cell Assay Cell Viability Assay[1]
Cell Types: CuFi-1 Cell
Tested Concentrations: 17.4 and 263.0 nM
Incubation Duration: 2 and 48 hrs (hours)
Experimental Results: Significant inhibition of ENaC measured in differentiated human bronchial epithelial cells at two short concentration conditions mediated Na+ transport (IC50= 263.0 nM) and long-term (IC50= 17.4 nM) treatment conditions.

Cell viability assay[1]
Cell Types: CuFi-1 Cell
Tested Concentrations: 0.3 μM
Incubation Duration: 72 hrs (hours)
Experimental Results: Cell viability in PEA-treated cells increased Dramatically to approximately 88% of control levels.

Cytotoxicity assay[1]
Cell Types: CuFi-1 Cell
Tested Concentrations: 0.001, 0.01, 0.03, 0.1, 0.3 and 1 μM
Incubation Duration: 72 hrs (hours)
Experimental Results: Provides PEA-mediated cytotoxicity against PEA in a dose-dependent manner over time Toxicity protection for 72 hrs (hours) with EC50 of 47.8 nM.
References

[1]. A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease. Cell Chem Biol. 2022 Jun 16;29(6):947-957.e8.

[2]. Clearing the air: Uniquely engaging furin as an approach to cystic fibrosis therapy. Cell Chem Biol. 2022 Jun 16;29(6):927-929.


Solubility Data


Solubility (In Vitro) DMSO : ~50 mg/mL (~87.49 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.5 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 2.5 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.7498 mL 8.7489 mL 17.4978 mL
5 mM 0.3500 mL 1.7498 mL 3.4996 mL
10 mM 0.1750 mL 0.8749 mL 1.7498 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.